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High-density lipoprotein (HDL) has been identified as a potential target in the treatment of atherosclerotic
vascular disease. The failure of torcetrapib, an inhibitor of cholesteryl ester transfer protein (CETP) that
markedly increased HDL levels in a clinical trial, has called into doubt the efficacy of HDL elevation. Recent
analysis suggests that failure may have been caused by off-target toxicity and that HDL is functional and
promotes regression of atherosclerosis. New studies highlight the central importance of the ATP-binding
cassette (ABC) transporters ABCA1 and ABCG1 in reducing macrophage foam cell formation, inflammation,
and atherosclerosis. A variety of approaches to increasing HDL may eventually be successful in treating
atherosclerosis.While statins have revolutionized the treatment of atherosclerotic
cardiovascular disease, they reduce cardiovascular events by
about 20%–40% depending on the degree of low-density lipo-
protein (LDL) reduction (Baigent et al., 2005; Kearney et al.,
2008), leaving a large burden of residual untreated disease.
There are extensive epidemiological data showing an inverse
relationship between high-density lipoprotein (HDL) levels and
coronary heart disease (CHD) (Castelli et al., 1977; Gordon
et al., 1977; Lewington et al., 2007; Rhoads et al., 1976), and
the HDL-raising properties of several lipid-lowering drugs, in-
cluding statins, fibrates, bile acid sequestrants, and niacin,
appear to be part of a spectrum of favorable effects (NHLBI,
1984; Brown et al., 2006; Otvos et al., 2006; Pedersen et al.,
1998). Recent studies show that in patients treated with statins
to lower LDL levels, HDL levels remain an independent predictor
of the likelihood of suffering cardiovascular events (Barter et al.,
2007a), and that in patients on statins with low LDL levels under-
going stent placement for acute coronary syndromes, HDL levels
at baseline are a strong predictor of 12-month morbidity and
mortality from cardiovascular events (Wolfram et al., 2006).
Transgenic overexpression of apoA-I in mice and infusion of
apoA-I/phospholipid complexes in humans cause reduced pro-
gression or regression of atherosclerosis (Nissen et al., 2003;
Plump et al., 1994; Rubin et al., 1991). These observations have
suggested that HDL-raising therapies might be an effective
way to reduce the huge burden of residual cardiovascular dis-
ease in patients treated with current lipid-lowering therapies.
A Disappointing Therapeutic Failure Involving the CETP
Inhibitor Torcetrapib
The hope for new HDL treatments was dealt a severe blow on
December 2, 2006, when a large clinical trial called ILLUMINATE
involving a potent HDL-raising drug, torcetrapib, was stopped
prematurely as a result of an excess of deaths and morbidity
from cardiovascular endpoints in the group receiving torcetrapib
and atorvastatin compared to atorvastatin alone. Torcetrapib
was at the forefront of a new class of drugs that potently raise
HDL and lower LDL levels by inhibiting cholesteryl ester transferprotein (CETP) (Brousseau et al., 2004), a therapeutic concept
that was first suggested by the dramatic high-HDL/low-LDL
phenotype of human genetic CETP deficiency (Brown et al.,
1989; Inazu et al., 1990). Unfortunately, torcetrapib also caused
a moderate increase in blood pressure (2–5 mm systolic blood
pressure) by an unknown mechanism (Barter et al., 2007b; Nis-
sen et al., 2007) that likely reflected an off-target effect, as hyper-
tension had not been observed in genetic CETP deficiency
(Zhong et al., 1996) and some other classes of CETP inhibitors
do not cause hypertension (Krishna et al., 2007; Kuivenhoven
et al., 2005). Thus, it was not clear whether the clinical failure
of torcetrapib was due to off-target toxicity or to a detrimental
mechanism of action (Rader, 2007a; Tall, 2007; Tall et al.,
2007). There has been considerable speculation that the strategy
of CETP inhibition might lead to formation of HDL that is dysfunc-
tional in terms of its ability to promote cholesterol efflux from
macrophage foam cells (Brewer, 2004; Ishigami et al., 1994),
that there might be a block in reverse cholesterol transport
(RCT) from peripheral tissues to liver and stool (Rader, 2007a),
or that HDL might be proinflammatory or pro-oxidant (Rader,
2007a; Singh et al., 2007). Here we will review recent clinical, cel-
lular, and transgenic mouse studies relevant to these questions.
These issues are also relevant to other approaches to raising
HDL since exercise, alcohol, statins, bile acid sequestrants,
and niacin all raise HDL at least in part by decreasing CETP levels
or in vivo activity (NHLBI, 1984; de Haan et al., 2008; Fumeron
et al., 1995; Morton and Greene, 1997; Schaefer and Asztalos,
2006; Seip et al., 1993). For example, HDL elevation in patients
taking statins or bile acid sequestrants may signal a lower level
of CETP-mediated transfer of HDL cholesteryl ester (CE) into
very low-density lipoprotein (VLDL) remnants that have been
cleared by upregulated hepatic LDL receptors.
A Recent Analysis of Clinical Data Identifies an
Off-Target Toxicity of Torcetrapib, While Coronary
Imaging Data Suggest Benefits of High HDL
Two recent reports have helped to elucidate whether the adverse
clinical outcome in ILLUMINATE was related to the moleculeCell Metabolism 7, May 2008 ª2008 Elsevier Inc. 365
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2007b; Nissen et al., 2007). The first report documents an
increase in mortality and morbidity from cardiovascular and
noncardiovascular causes in patients receiving torcetrapib and
atorvastatin (T+A) compared to atorvastatin (A) alone (Barter
et al., 2007b). Torcetrapib therapy was associated with a signifi-
cant worsening of the primary cardiovascular endpoint (the time
to the first major cardiovascular event, including myocardial in-
farction, unstable angina, revascularization, and heart failure)
as well as in total deaths, including an apparent excess of deaths
from cancer and infectious disease. The excess of deaths from
infectious disease and cancer in the group receiving torcetrapib
was not paralleled by a similar increase in infections or cancers
reported as adverse events, raising the possibility that these
deaths resulted from torcetrapib-related cardiovascular toxicity
as a terminal event complicating cancer or infection. However,
HDL is known to modulate acute-phase responses, and it is
conceivable that very high HDL in subjects treated with CETP
inhibitors could dampen the inflammatory response to a severe
infection (Rader, 2007a).
This study also revealed that patients receiving torcetrapib
had significant reductions in serum potassium levels and in-
creases in bicarbonate and in serum aldosterone levels (Barter
et al., 2007b). While blood pressure changes were not predictive
of clinical outcome, there was an excess of deaths and cardio-
vascular events in patients whose decreases in serum potassium
or increases in serum bicarbonate levels were more than the
median. In contrast, in patients who experienced the largest
increases in HDL (i.e., above the median), there appeared to
be a modest decrease in the primary cardiovascular endpoint.
Aldosterone has a wide spectrum of vascular toxicities, including
increased atherosclerosis (Keidar et al., 2004). Even though the
difference in serum potassium levels between the T+A and A
groups was small (0.1 mM), the levels were similar in magnitude
to those seen in clinical trials of aldosterone antagonists for heart
failure after myocardial infarction, in which the slight increases in
serum potassium levels were associated with a beneficial clinical
outcome (Pitt et al., 2003). The mechanisms of hyperaldosteron-
ism are uncertain, but increases in aldosterone have been seen
in torcetrapib-treated rats that naturally lack CETP. These stud-
ies strongly suggest significant off-target toxicity of torcetrapib
related to hyperaldosteronism and hypokalemia. They also ap-
pear to be inconsistent with the hypothesis that direct toxic
effects of HDL were responsible for the adverse cardiovascular
outcome. However, unknown mechanism-related adverse ef-
fects of CETP inhibition on cardiovascular events could still be
involved in the negative results of this study (Barter et al., 2007b).
In addition to the ILLUMINATE study, parallel imaging studies
of coronaries and carotids showed no difference in the primary
measures of atherosclerosis. However, there was a significant
decrease in a secondary endpoint, measurement of coronary
atherosclerosis volume (Nissen et al., 2007). Interestingly, a re-
cent post hoc analysis showed that in the T+A group, there
was a significant inverse relationship between the change in
HDL cholesterol level and the primary measure of atherosclero-
sis, i.e., the percent atheroma volume (Nicholls et al., 2007). In-
deed, there was significant regression of atherosclerosis in
patients with the largest increases in HDL levels. There was no
relationship between change in HDL and percent atheroma366 Cell Metabolism 7, May 2008 ª2008 Elsevier Inc.volume in the A group, suggesting that the effect was specific
to torcetrapib treatment. Stratification of the data by change in
serum potassium level revealed a substantial beneficial effect
on percent atheroma volume in patients with the largest in-
creases in HDL levels whose change in potassium was above
the median. The intravascular ultrasound results appear to paral-
lel the clinical outcome in ILLUMINATE and provide a strong
suggestion that maximal HDL increases mediated by CETP inhi-
bition reduce the volume of coronary atherosclerosis. However,
these suggestions based on post hoc analyses (Barter et al.,
2007b; Nissen et al., 2007; Nicholls et al., 2007) are only useful
for generating hypotheses. They indicate that it may be worth-
while to evaluate other classes of CETP inhibitors that do not
cause hyperaldosteronism or hypertension in randomized clini-
cal trials. They also suggest that the maximal benefit of such
HDL-raising therapies may only be attained at very high HDL
cholesterol levels > 60 mg/dl. Interestingly, this parallels earlier
observations on the relationship between genetic CETP defi-
ciency and CHD, where a beneficial association was only appar-
ent in subjects with HDL cholesterol > 60 mg/dl (Zhong et al.,
1996). Similarly, CETP single-nucleotide polymorphisms that
are associated with slightly higher HDL levels in the general pop-
ulation are not associated with significant alterations in CHD risk
(Willer et al., 2008).
The Role of HDL, ABCA1, and ABCG1 in Macrophage
Cholesterol Efflux
The ability of HDL and its major apolipoprotein, apoA-I, to stim-
ulate efflux of cholesterol from macrophage foam cells in ather-
omatous blood vessels is thought to be central to its antiathero-
genic mechanism and to represent the first step in an overall
process of RCT (Figure 1). The ATP-binding cassette (ABC)
transporter ABCA1, the mutant molecule in Tangier disease
(Bodzioch et al., 1999; Brooks-Wilson et al., 1999; Rust et al.,
1999), promotes net cholesterol efflux to lipid-poor apoA-I, while
ABCG1 facilitates net cholesterol efflux to HDL particles (Ken-
nedy et al., 2005; Wang et al., 2004). Deficiency of CETP results
in a prominent increase in larger HDL-2 particles, and in com-
plete CETP deficiency, there is a marked increase in the apoE-
HDL fraction. HDL isolated from subjects with homozygous
CETP deficiency showed enhanced ability to promote choles-
terol efflux from macrophage foam cells. Depletion of apoE
from the HDL fraction decreased its cholesterol efflux potential,
and knockdown of macrophage ABCG1 also substantially re-
duced cholesterol efflux to HDL from CETP-deficient subjects
(Matsuura et al., 2006). Mahley, Weisgraber, and coworkers
(Mahley et al., 2006; Peters-Libeu et al., 2006) have shown that
in reconstituted HDL particles, apoE resides in a superficial loca-
tion among the phosphorylcholine head groups of phospholipids
in contrast to more deeply embedded apoA-I molecules and
have speculated that this may endow flexibility in the surface
of HDL, permitting expansion of the core of HDL with CE as
the lecithin:cholesterol acyltransferase (LCAT) reaction pro-
ceeds (Mahley et al., 2006). Importantly, a study of the choles-
terol efflux potential of HDL isolated from subjects treated with
torcetrapib showed moderately increased mean cholesterol
efflux from macrophages using HDL from patients treated with
the 60 mg dose (the dose used in phase 3 torcetrapib clinical
studies), primarily due to an increase in HDL concentration, while
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ReviewFigure 1. Role of HDL in Macrophage
Cholesterol Efflux and Reverse Cholesterol
Transport
Lipid-free or lipid-poor apolipoprotein A-I (apoA-I)
can interact with the ATP-binding cassette (ABC)
transporter A1 (ABCA1) in macrophage foam cells
in atheroma, promoting efflux of free cholesterol
(FC) and phospholipids (PL). This results in the
formation of nascent high-density lipoprotein
(HDL) particles that are further modified by leci-
thin:cholesterol acyltransferase (LCAT), generat-
ing cholesteryl esters (CE) and forming mature
HDL. HDL particles are also formed by ABCA1 in
the liver and intestine (not shown). Mature HDL
particles can serve as acceptors for ABCG1-
mediated cholesterol efflux; there is also choles-
terol efflux to mature HDL by passive efflux (Yan-
cey et al., 2003) and possibly other transporters
as well. In humans and some other species, CE
in HDL can be transferred to apoB-containing lipoproteins by cholesteryl ester transfer protein (CETP) and remnant lipoproteins subsequently cleared by
low-density lipoprotein (LDL) receptors in the liver. Finally, HDL cholesterol can be taken up by the liver and subsequently secreted into the bile in a process
that may involve selective lipid uptake by scavenger receptor BI (SR-BI). SR-BI is important in mice and rats, but its significance in humans is unknown.HDL from subjects treated with a higher dose of 120 mg showed
substantially greater cholesterol efflux potential due to both an
increase in HDL concentration and an increased cholesterol
efflux potential per unit mass HDL. More subjects showed an
increase in apoE and LCAT in the HDL-2 at the higher dose,
and the greater the increase in HDL level, the more the enrich-
ment with apoE and LCAT (Yvan-Charvet et al., 2007a). These
findings suggest that, at least in terms of cholesterol efflux po-
tential monitored in these assays, HDL has normal or enhanced
functionality (Matsuura et al., 2006; Yvan-Charvet et al., 2007a),
paralleling the observation that subjects with larger HDL in-
creases on torcetrapib showed more pronounced regression
of coronary atherosclerosis (Nicholls et al., 2007).
A limitation of cell culture studies is that they are a static sys-
tem. In vivo, the process of CE-triglyceride exchange mediated
by CETP may be important in regenerating lipid-poor apoA-I to
serve as substrate for ABCA1, and thus CETP inhibition could
potentially have an adverse effect on ABCA1-mediated choles-
terol efflux from foam cells (Wang et al., 2001). However, plasma
apoA-I levels are increased in CETP deficiency, and the concen-
tration of the pre-beta HDL fraction that may in part represent
lipid-poor apoA-I is preserved or increased (Asztalos et al.,
2004; Duverger et al., 1995; Inazu et al., 1990). Interestingly, pa-
tients treated with torcetrapib who had larger increases in apoA-I
levels appeared to have better cardiovascular outcomes (Barter
et al., 2007b). CETP deficiency probably increases plasma
apoA-I levels by increasing HDL size and delaying catabolism
of apoA-I (e.g., by decreasing renal filtration) (Ikewaki et al.,
1993). There may be sufficient local remodeling of HDL in the
arterial wall by lipases and phospholipid transfer protein (PLTP)
secreted by macrophages to regenerate lipid-poor apoA-I (To-
bias and Curtiss, 2005). This could lead to enhanced activities
of both ABCA1 and ABCG1 lipid efflux pathways from foam cells
in atheroma (Figure 2). Thus, CETP inhibition may enhance cho-
lesterol efflux from macrophage foam cells via ABCG1, passive
efflux, and ABCA1 pathways, leading to a regression of coronary
atheroma at high levels of HDL.
CETP and Reverse Cholesterol Transport
While these studies highlight the likely beneficial effects of CETP
deficiency on cholesterol efflux from foam cells, CETP inhibitionin rabbits and humans does not stimulate the overall process of
RCT (Brousseau et al., 2005). In fact, a recent study of macro-
phage RCT (the rate of movement of [3H]cholesterol from macro-
phages injected into the peritoneal cavity into serum, liver, and
feces) showed that adeno-associated virus (AAV)-CETP in-
creased overall RCT in mice as measured by the movement of
[3H]cholesterol from macrophages into feces. The initial steps
of [3H]cholesterol movement from macrophages to serum were
not significantly changed by CETP expression. This apparent
stimulation of RCT into stool by AAV-CETP was not observed
in Ldlr/mice, suggesting that CETP enhances RCT by promot-
ing the movement of CE from HDL into apoB-containing lipopro-
teins with subsequent removal of remnants by LDLR (Tanigawa
et al., 2007). One implication of these studies could be that
in subjects treated with high doses of statins, upregulation of
LDLR might play a pivotal role in CETP-mediated RCT, and
thus the combination of CETP inhibitors and statins might have
an adverse effect on RCT (Barter et al., 2007b; Nissen et al.,
2007).
It is important to note, however, that the macrophage RCT
method does not measure net fluxes of sterol, and movements
of radioactivity may reflect isotope exchange processes that
are responding to changes in sterol pool sizes in plasma or liver.
For example, CETP expression appreciably lowered plasma
cholesterol levels in Ldlr+/+ mice, but not in Ldlr/ mice (Tani-
gawa et al., 2007). Thus, the specific activity of macrophage-
derived [3H]cholesterol in plasma is higher in CETP transgenic
mice versus nontransgenic mice on a Ldlr+/+ background, but
not in Ldlr/ mice. The ability of CETP to increase movement
of [3H]cholesterol radioactivity from plasma into stool in the
Ldlr+/+ group might arise from the higher specific activity without
indicating an increase in net flux of plasma sterol into feces in the
group expressing CETP. Net sterol outputs were not reported in
the Tanigawa et al. (2007) study. Moreover, the Tanigawa et al.
(2007) studies in mice contrast with the earlier findings that fecal
neutral sterol and bile acid excretion were not appreciably
changed in humans treated with high doses of torcetrapib,
whether or not the subjects received concomitant treatment
with atorvastatin (Brousseau et al., 2005). In summary, it is likely
that in the steady state, CETP inhibition does not change the
overall rate of flux of cholesterol from peripheral tissues to liverCell Metabolism 7, May 2008 ª2008 Elsevier Inc. 367
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ABCA1 and ABCG1 Transporters
Inhibition or genetic deficiency of CETP leads to accumulation of larger HDL in the plasma compartment due to impaired clearance of particles in the kidney and
liver (Ikewaki et al., 1993). The reduction in catabolism of HDL-associated apoA-I leads to an increased pool of apoA-I and entry of increased numbers of large
HDL particles into the artery wall. On entering the subendothelial space, large particles can act as acceptors for ABCG1-mediated cholesterol efflux, and there
may also be sufficient local remodeling of HDL in the arterial wall by lipases (HL) and phospholipid transfer protein (PLTP) secreted by macrophages (Curtiss et al.,
2006) to regenerate lipid-poor apoA-I, which in turn could also enhance the ABCA1 lipid efflux pathway from macrophage foam cells in atheroma. In addition,
large HDL may promote efflux of cholesterol and oxysterols from endothelial cells, which express abundant ABCG1 (Hassan et al., 2006).or stool; however, the pathway of cholesterol transport is altered,
favoring transport in HDL and direct uptake in the liver rather than
the indirect pathway of RCT involving transfer to the liver via
VLDL/LDL (Figure 1). In this regard, the high-affinity binding of
apoE-rich HDL to LDLR in CETP deficiency (Yamashita et al.,
1990) and scavenger receptor BI (SR-BI)-mediated selective up-
take of HDL CE (Trigatti et al., 2003) could play significant roles.
In addition, the CE content of VLDL and intermediate-density
lipoprotein (IDL) (remnant) particles is reduced, and the level of
LDL is decreased due to increased hepatic uptake and possibly
decreased conversion of VLDL to LDL (Ikewaki et al., 1995).
Thus, any potential benefit of CETP inhibition derives not from
an overall increase in RCT but rather from an altered lipoprotein
profile with increased HDL and reduced levels of cholesterol in
remnants and LDL, with consequent favorable interactions with
cells in the arterial wall.
The Role of Different Cholesterol Efflux Pathways
in Atherosclerosis
Several different potential cholesterol efflux pathways from mac-
rophages to HDL have been described: passive or diffusional
efflux, efflux associated with macrophage apoE secretion, SR-
BI-mediated cholesterol efflux, and active cholesterol efflux
mediated by the ABC transporters ABCA1 and ABCG1 (Tall,
2003; Yancey et al., 2003). Recent studies from several different
laboratories indicate that together, ABCA1 and ABCG1 have the
major role in mediating net cholesterol efflux from macrophages
to HDL or serum (Adorni et al., 2007; Out et al., 2008b; Wang368 Cell Metabolism 7, May 2008 ª2008 Elsevier Inc.et al., 2007; Yvan-Charvet et al., 2007b, 2008). When one trans-
porter is deficient, the other is induced as a result of sterol accu-
mulation and liver X receptor (LXR) activation, resulting in mutual
compensation in the activities of the two transporters (Ranalletta
et al., 2006; Yvan-Charvet et al., 2007a). Macrophages with
combined deficiency of ABCA1 and ABCG1 have major defects
in cholesterol efflux to apoA-I, HDL, and serum, as well as in
apoE secretion (Out et al., 2008b; Yvan-Charvet et al., 2007b).
In one study, combined deficiency of ABCA1 and ABCG1 re-
sulted in a 60% decrease in macrophage net cholesterol efflux
to HDL (Yvan-Charvet et al., 2007b), while in another study, the
decrease in cholesterol efflux was reported as 100% (Out
et al., 2008b). A third set of studies suggested major roles of
ABCA1 and ABCG1 in cholesterol-loaded macrophages and
a relatively larger role of passive cholesterol efflux from cells to
HDL, especially when macrophages are not loaded with choles-
terol (Adorni et al., 2007). Compared to wild-type mice or mice
with single deficiencies of ABCA1 or ABCG1, mice with com-
bined deficiency of ABCA1 and ABCG1 showed much greater
accumulation of cholesterol in the form of CE in peritoneal
macrophages on either chow or high-cholesterol diets, as well
as foam cell accumulation in various organs such as the spleen
(Out et al., 2008a, 2008b; Yvan-Charvet et al., 2007b). Moreover,
parallel studies of macrophage RCT showed major and additive
effects of macrophage deficiency of ABCA1 and ABCG1 on
movement of radiotracer into serum, liver, and feces (Wang
et al., 2007). Since ABCA1 and ABCG1 mediate unidirectional
cholesterol efflux from cells to HDL and HDL (Wang et al.,
Cell Metabolism
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studies provide a minimum estimate of the contribution of
ABCA1 and ABCG1 to macrophage cholesterol efflux to serum
in vivo. Together, these recent studies have confirmed that
ABCA1 and ABCG1 account for the major portion of the net cho-
lesterol efflux from cholesterol-loaded macrophages to plasma
lipoproteins in vivo.
The atherosclerosis studies provide a close parallel with the
cholesterol efflux data and indicate that combined deficiency
of ABCA1 and ABCG1 in bone marrow-derived cells results in
a dramatic enhancement of atherosclerosis. Transplantation of
Abca1/ bone marrow into Ldlr/ or Apoe/ mice results in
a modest increase in atherosclerosis (Aiello et al., 2002; van
Eck et al., 2002). In contrast, transplantation of Abcg1/ bone
marrow into Ldlr/ orApoe/mice resulted in either no change
or a decrease in atherosclerosis (Baldan et al., 2006; Out et al.,
2008a; Ranalletta et al., 2006). The decrease in atherosclerosis
was attributed to either compensatory upregulation of ABCA1
in Abcg1/ macrophages (Ranalletta et al., 2006) or enhanced
apoptosis of Abcg1/ macrophages (Baldan et al., 2006). Im-
portantly, transplantation of Abca1/Abcg1/ bone marrow
into Ldlr+/ mice followed by feeding a high-cholesterol diet
(1.25% cholesterol and 1% cholic acid) led to markedly in-
creased atherosclerosis compared to mice receiving bone
marrow with single knockout (KO) of ABCA1 or ABCG1 (Yvan-
Charvet et al., 2007b). In addition, there was prominent accu-
mulation of foam cells in the heart, spleen, and small intestine
(Yvan-Charvet et al., 2007b). A similar study (Out et al., 2008a)
involved transplantation of Abca1/Abcg1/ bone marrow
into Ldlr/ mice fed a Western-type diet (0.15% cholesterol
and saturated fat). This study also documented an increase in
foam cells in various organs including spleen, small intestine,
Peyer’s patches, and liver. However, in contrast to the aforemen-
tioned study (Yvan-Charvet et al., 2007b) wherein plasma VLDL
and LDL levels were similar in mice receiving wild-type or dou-
ble-KO bone marrow, plasma VLDL and LDL levels in this study
(Out et al., 2008a) were markedly decreased in the double-KO
recipients, with differences between the studies probably re-
flecting the different cholesterol content of the diets. Nonethe-
less, atherosclerosis was increased in the double-KO recipients
relative to the level of plasma cholesterol (Out et al., 2008a).
Cellular Mechanisms of Cholesterol Efflux
via ABCA1 and ABCG1
ABCA1 promotes efflux of phospholipids and cholesterol to
lipid-poor apoA-I in a process that involves the direct binding
of apoA-I to the transporter (Oram et al., 2000; Wang et al.,
2000). Most likely ABCA1 translocates phospholipids from the
inner to the outer membrane leaflet of the plasma membrane,
perhaps creating outward curvature and packing defects in the
membrane; this may allow interpolation of amphipathic helices
of apoA-I into the membrane and formation of nascent HDL par-
ticles (Vedhachalam et al., 2007). Cholesterol and phospholipid
efflux via ABCA1 appear to occur simultaneously (Smith et al.,
2004), and it is possible that the transporter also translocates
cholesterol onto the forming HDL particle (Gillotte-Taylor et al.,
2002). In contrast, ABCG1 promotes efflux of cholesterol onto
a variety of lipoprotein particles, including HDL, LDL, phospho-
lipid vesicles, and cyclodextrin, but does not appear to bindlipoprotein particles (Wang et al., 2004, 2006). Overexpression
of ABCG1 also promotes efflux of choline-containing phospho-
lipids onto HDL (Wang et al., 2004), likely including both sphingo-
myelin and phosphatidylcholine (Kobayashi et al., 2006). Follow-
ing activation of LXRs in macrophages, the ability of ABCG1 to
promote cholesterol efflux correlates with the appearance of
ABCG1 in the plasma membrane (Wang et al., 2006).
Two potential mechanisms of sterol efflux by ABCG trans-
porters have been proposed (Figure 3):
(1) Small (2003) has suggested that ABCG5 and ABCG8, het-
erodimeric transporters that promote secretion of cholesterol
and plant sterols into bile, mediate protrusion of the hydro-
phobic sterol molecule into the aqueous phase, followed by
collision with a micelle. By analogy, ABCG1 could promote
protrusion of cholesterol from the plasma membrane fol-
lowed by transient collision with an HDL particle (Figure 3A).
Since there is very little energetic barrier to the movement
of cholesterol between the two leaflets of a bilayer membrane
(Small, 2003), it seems unlikely that ABCG1 simply trans-
locates cholesterol from the inner to the outer plasma
membrane.
(2) Alternatively, ABCG1 could change the organization of
phospholipids in the plasma membrane such that the mem-
brane more readily releases sterol and phospholipids to
lipoprotein acceptors (Figure 3B). This model is consistent
with the nonspecific nature and lack of binding of lipoprotein
acceptors by ABCG1.
It is notable that ABCG1 appears to promote movement of
cholesterol from the ER to the plasma membrane, manifested
as decreased cellular ACAT activity and decreased activity of
SREBP-2 target genes, even in the absence of extracellular lipo-
protein acceptors (Wang et al., 2006). Thus, ABCG1 appears to
increase the affinity of the plasma membrane for ER-derived
sterols even while releasing sterols more readily to extracellular
lipoprotein acceptors (Wang et al., 2006), perhaps secondary
to translocation and efflux of membrane phospholipids.
A Potential Role of HDL and ABCG1 in Macrophage
Apoptosis and Inflammation in Plaques
Ruptured atherosclerotic plaques are characterized by thin
caps, large necrotic cores, and increased numbers of apoptotic
macrophages and smooth muscle cells. HDL was found to
protect macrophages from apoptosis induced by oxidized LDL,
or by loading with free cholesterol (Cui et al., 2007; Terasaka
et al., 2007). In the case of oxidized LDL-induced apoptosis,
the protective effect of HDL was abolished in Abcg1/ macro-
phages (Terasaka et al., 2007). In contrast, for free cholesterol
(FC)-induced apoptosis, knockout of both ABCG1 and ABCA1
was required to see an abolition of the protective effect of HDL
(Yvan-Charvet et al., 2007a). ABCG1 has a specific role in pro-
moting cellular efflux of sterols modified at the 7 position such
as 7-ketocholesterol (7-KC; Terasaka et al., 2007). 7-KC is a
spontaneously formed cholesterol oxidation product that is
present in processed foods and high-cholesterol diets and is
the most abundant oxysterol in oxidized LDL and in human
atherosclerotic plaques (Brown et al., 1996; Brown and Jessup,
1999; Vine et al., 1998). Dietary 7-KC is normally absorbed onCell Metabolism 7, May 2008 ª2008 Elsevier Inc. 369
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ReviewFigure 3. Two Proposed Mechanisms of ABCG1-Mediated Sterol Efflux
(A) One model suggests that ABCG transporters accomplish FC transfer by helping sterol molecules to overcome the energy barrier for entry into the hydrophilic
water layer perhaps by utilizing ATP to promote protrusion of the cholesterol molecule into water, followed by a transient collision with an acceptor (Small, 2003),
in this case HDL.
(B) In the second model, the ability of ABCG1 to promote PL efflux (Kobayashi et al., 2006) points to a function as a phospholipid flippase mediating the transfer of
PL from the inner to the outer leaflet (I). This could lead to such an extensive change in the equilibrium of membrane components that the outer leaflet becomes
more attractive to sterol (e.g., an increased content of sphingomyelin or saturated phosphatidylcholine), followed by transbilayer diffusion of cholesterol mole-
cules toward the outer leaflet (II), where they can dissociate onto HDL particles perhaps following nonspecific binding of HDL to the plasma membrane (III) (Tabas
and Tall, 1984).
In both models, the movement of cholesterol from the inner to the outer membrane is followed by carrier-facilitated diffusion from cellular organelles, notably the
endoplasmic reticulum (ER; IV), leading to altered sterol-mediated ER regulation of cholesterol homeostasis (Maxfield and Menon, 2006; Wang et al., 2006).chylomicrons, rapidly cleared from the circulation in remnants,
and converted into bile salts in the liver. However, 7-KC is appar-
ently cytotoxic at some concentrations found in vivo, inducing
apoptosis and necrosis of endothelial cells and macrophages.
HDL and ABCG1 have a specific role in promoting efflux of
7-KC and 7-b-OH cholesterol in transfected 293 cells and mac-
rophages, while ABCA1 and apoA-I have no ability to stimulate
efflux of these oxysterols (Terasaka et al., 2007). Other oxyster-
ols such as 25-OH cholesterol can undergo efflux by both
ABCA1 and ABCG1 pathways. Moreover, Abcg1/ mice fed
a Western diet showed prominent accumulation of 7-KC in
macrophages (Terasaka et al., 2007). ABCG1 is also highly ex-
pressed in endothelial cells (O’Connell et al., 2004). The role of
ABCG1 in promoting efflux of 7-KC suggests that large HDL-2
particles that promote sterol efflux via ABCG1 may have a partic-
ular role in protecting endothelial cells and macrophages from
the deleterious effects of oxysterols consumed in the diet or
formed on LDL (Terasaka et al., 2007). This could be important
in maintaining normal endothelial functions and in atheroscle-
rotic plaque stabilization (Libby et al., 2002).
In addition to the severe defect in cholesterol efflux and apoE
secretion, Abca1/Abcg1/ macrophages showed increased
mRNA and secretion of chemokines and inflammatory cytokines
(Yvan-Charvet et al., 2007b). Single KO of ABCG1 produced
a similar, though milder, defect in secretion of inflammatory cy-
tokines and chemokines, while KO of ABCA1 had minimal effects
(Yvan-Charvet et al., 2007b). The HDL/ABCG1 pathway may
have a specific role in decreasing macrophage inflammatory
and chemokine responses (Yvan-Charvet et al., 2007b). Thus,370 Cell Metabolism 7, May 2008 ª2008 Elsevier Inc.HDL/ABCG1 may be important in protecting advanced plaques
from macrophage apoptosis and inflammatory responses, sug-
gesting a role in plaque stabilization and acute coronary
syndromes.
Other potential anti-inflammatory properties of HDL may be
related to its ability to take up oxidized phospholipids from other
lipoproteins or cells and to its content of PAF acetylhydrolase
(also known as lipoprotein-associated PLA-2), an enzyme that
can break down short-chain oxidized phospholipids. In Apoe/
mice, the ability of HDL to promote migration of dendritic cells
out of the skin (Angeli et al., 2004), and perhaps by inference
from arteries, may depend on its content of PAF acetylhydrolase
(Karasawa, 2006). While the antioxidant and anti-inflammatory
properties of HDL may be important in its antiatherogenic ef-
fects, oxidative and inflammatory processes may themselves
impair the function of HDL. Thus, HDL isolated from subjects
with coronary artery disease may lose its anti-inflammatory
properties (Vaisar et al., 2007). Modification of apoA-I by macro-
phage-derived myeloperoxidase can lead to chlorination of
apoA-I on specific amino acid residues and an impairment of
cholesterol efflux by ABCA1 (Shao et al., 2005, 2006; Zheng
et al., 2004, 2005).
Multiple Steps in the Pathogenesis of Atherosclerosis
May Be Beneficially Affected by HDL
Atherosclerosis is initiated by the retention of apoB-containing
lipoproteins on proteoglycans in the arterial matrix in thickened
areas of the arterial intima (Gustafsson and Boren, 2004; Tabas
et al., 2007). Subsequent modification of LDL by aggregation
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ReviewFigure 4. Potential Protective Effects of HDL on the Different Steps of Atherogenesis and Plaque Disruption
HDL can compete with the proteoglycan-rich matrix for binding of LDL particles limiting their retention (1) and can inhibit their modification by aggregation
or oxidation, preventing a cascade of events that comprise the macrophage-dominated inflammatory process that triggers the cascade of events leading to
atherosclerosis (2). HDL inhibits the attraction of monocytes to the endothelium by downregulating the expression of the chemoattractant cytokine MCP-1
(3). The binding of monocytes to the endothelium can also be inhibited by HDL by downregulation of the expression of the cell adhesion molecules VCAM-1
and ICAM-1 (4) and upregulation of endothelial cell nitric oxide (NO) release (5). HDL promotes macrophage cholesterol efflux via ABCA1 and ABCG1 (6) and
thus reduces macrophage expression of inflammatory cytokines (7) as well as macrophage apoptosis induced by loading with unesterified cholesterol or oxidized
LDL (8). Finally, HDL may help to preserve the viability of phagocytic macrophages by promoting massive cholesterol efflux after ingestion of cholesterol-enriched
apoptotic cells (9), preventing postapoptotic necrosis with consequent inflammatory effects that contribute to plaque rupture.or oxidation leads to a cascade of events that comprise the mac-
rophage-dominated modified inflammatory response of athero-
sclerosis. Almost every step in this process has been reported
to be favorably influenced by HDL. apoE-containing HDL can
compete with the proteoglycan-rich matrix for binding of LDL
(Figure 4, step 1) (Saxena et al., 1993), and HDL and apoA-I
can inhibit LDL aggregation (Khoo et al., 1990). Moreover, HDL
and its major apolipoprotein apoA-I have a variety of antioxidant
properties that can reduce oxidation of LDL (step 2) (Navab et al.,
2000a, 2000b; Watson et al., 1995). Oxidized phospholipids, hy-
percholesterolemia, and disturbed blood flow induce activation
of endothelial cell NF-kB, resulting in upregulation of MCP-1,
VCAM-1, and ICAM-1, causing attraction and binding of mono-
cytes to the endothelium (Libby, 2002). HDL can inhibit the bind-
ing of monocytes to the endothelium by downregulating expres-
sion of cell adhesion molecules (Cockerill et al., 1995) (step 4). A
variety of studies indicate that HDL enhances endothelial cell ni-
tric oxide (NO) release (Assanasen et al., 2005; Gong et al., 2003;
Nofer et al., 2004; Yuhanna et al., 2001), and NO can inhibit the
binding of monocytes to the endothelium (step 5). LDL modified
by aggregation or oxidation can be taken up by macrophages,
inducing foam cell formation. HDL promotes macrophage cho-
lesterol efflux via ABCA1 and ABCG1, and probably other path-
ways as well (step 6). As noted above, HDL and apoA-I acting via
ABCA1 and ABCG1 likely reduce macrophage expression of
inflammatory genes and chemokines (step 7). ABCG1 is highly
expressed in vascular endothelium, and this could be relevant
to the mechanisms by which HDL can reduce expression of
cell adhesion molecules (Hassan et al., 2006; O’Connell et al.,
2004). The activity of these two transporters also reduces apo-ptosis of macrophages induced by loading with unesterified cho-
lesterol or oxidized LDL (step 8) (Terasaka et al., 2007). Finally,
the clearance of cholesterol-loaded apoptotic cells by phago-
cytic macrophages is important in preventing postapopotic
necrosis and inflammation (Tabas, 2005). Macrophages that
have phagocytosed cholesterol-enriched apoptotic cells show
marked induction of ABCA1 and ABCG1 expression (step 9)
and massive cholesterol efflux, which helps to preserve their
viability, likely preventing oxysterol- and FC-induced toxicity in
phagocytes (Cui et al., 2007; Gerbod-Giannone et al., 2006).
Conclusion and Perspective
The failure of the ILLUMINATE study represents a watershed in
the development of HDL-directed therapies. Different observers
have had very different reactions to this study and its adverse
outcome. On the one hand, the failure could signal the end of
the quest for HDL-directed therapies and lead to refocusing on
newer mechanisms of VLDL/LDL lowering (Cohen et al., 2006;
Cuchel et al., 2007; Tall, 2006) or vessel wall targets. On the other
hand, the post hoc analyses of the torcetrapib studies strongly
suggest that sufficient increases in large HDL-2 particles may
lead to a regression of coronary atherosclerosis and have iden-
tified a plausible mechanism of off-target toxicity of torcetrapib.
These findings suggest that HDL increases due to CETP inhibi-
tors, and perhaps by analogy niacin, may result in functional
HDL. In parallel, basic research has revealed the importance of
the ABCG1 pathway in mediating cellular sterol efflux to such
large HDL particles. Treatments that increase cholesterol efflux
via ABCA1 and/or ABCG1 are likely to be beneficial for athero-
sclerosis, though perhaps with a different spectrum of clinicalCell Metabolism 7, May 2008 ª2008 Elsevier Inc. 371
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Revieweffects. Drugs that increase expression of apoA-I in the liver, or
infusion of apoA-I or peptides derived from apoA-I that have
been optimized for interaction with ABCA1 or LCAT, are also
likely to be beneficial (Belalcazar et al., 2003; Linsel-Nitschke
and Tall, 2005; Navab et al., 2006; Nissen et al., 2003; Rader,
2007b). These approaches may also lead to increased formation
and levels of HDL particles that can in turn promote efflux of
sterols via ABCG1. Therapeutic strategies that upregulate both
ABCA1 and ABCG1 transporters may also be beneficial, as low
levels of the transporters themselves may be rate limiting for cel-
lular cholesterol efflux in some subjects with CHD (Trogan et al.,
2006). Thus, assuming problems of increased fatty liver can be
solved (Repa et al., 2000; Schultz et al., 2000), LXR activators
might be ideal agents for increasing a variety of molecules
involved in cholesterol efflux and transport (Bradley et al.,
2007; Scott, 2007)—for example, restricting LXR activation to
the small intestine might result in an increase in intestinal HDL
formation via ABCA1, without producing fatty liver (Brunham
et al., 2006).
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